Contineum Therapeutics (CTNM) Profit After Tax (2023 - 2026)

Contineum Therapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$14.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 9.38% year-over-year to -$14.5 million; the TTM figure through Mar 2026 stood at -$58.5 million (down 17.41% YoY), while the FY2025 annual figure was -$60.0 million, down 41.93% from the prior year.
• Profit After Tax was -$14.5 million for Q1 2026 at Contineum Therapeutics, up from -$15.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $41.6 million in Q2 2023 to a low of -$16.0 million in Q2 2025.
• Historically, Profit After Tax has averaged -$7.2 million across 4 years, with a median of -$10.3 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Profit After Tax plunged 121.68% in 2024, then advanced 9.38% in 2026.
• A 4-year view of Profit After Tax shows it stood at -$7.8 million in 2023, then slumped by 87.48% to -$14.6 million in 2024, then fell by 4.21% to -$15.2 million in 2025, then advanced by 4.47% to -$14.5 million in 2026.
• The last three Profit After Tax figures came in at -$14.5 million (Q1 2026), -$15.2 million (Q4 2025), and -$12.8 million (Q3 2025), per Business Quant data.